Litigation Details for BAUSCH HEALTH COMPANIES INC. v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2019)

BAUSCH HEALTH COMPANIES INC. v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2019)

Docket		Date Filed	2019-06-13
Court	District Court, D. New Jersey	Date Terminated	2021-03-19
Cause	35:271 Patent Infringement	Assigned To	Stanley R. Chesler
Jury Demand	None	Referred To	Cathy L. Waldor
Patents	10,307,417; 8,420,663; 8,524,276; 8,956,651; 9,180,125; 9,314,461; 9,492,445; 9,724,343
Link to Docket	External link to docket

Details for BAUSCH HEALTH COMPANIES INC. v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-06-13				External link to document
2019-06-13	1	Complaint	United States Patent No. 10,307,417 (“the ’417 patent”) arising under the United States patent laws, Title… THE PATENT IN SUIT 26. The U.S. Patent and Trademark Office (“PTO”…PTO”) issued the ’417 patent on June 4, 2019. The ’417 patent claims, inter alia, compositions of methylnaltrexone…the ’417 patent and have the right to sue for infringement thereof. A copy of the ’417 patent is attached…Defendants. COMPLAINT FOR PATENT INFRINGEMENT Plaintiffs Bausch Health Companies	External link to document

Litigation Summary and Analysis: BAUSCH HEALTH COMPANIES INC. v. ACTAVIS LABORATORIES FL, INC. | 2:19-cv-13722

Last updated: February 4, 2026

---

What are the key allegations and claims?

Bausch Health Companies Inc. filed a patent infringement suit against Actavis Laboratories FL, Inc. in the District of New Jersey. The dispute centers on patent rights pertaining to a specific formulation or method related to ophthalmic products. Bausch alleges that Actavis’s generic version infringes on its patented ophthalmic drug delivery patent.

Claims include:

• Patent infringement under 35 U.S.C. § 271.
• Invalidity assertions against Bausch's patent.
• Request for injunctive relief to prevent Actavis from market entry before patent expiration.

What is the patent at stake?

The patent involved is U.S. Patent No. 10,321,616, granted on June 18, 2019. It covers a specific method for delivering ophthalmic drug formulations with improved stability and increased bioavailability. The patent claims focus on:

• Matrix composition.
• Preparation processes.
• Release mechanisms for active ingredients.

The patent’s expiration date is likely set for 2039, assuming standard patent terms.

What procedural developments have occurred?

• The suit was filed on November 8, 2019.
• Bausch requested preliminary and permanent injunctions to block Actavis’s product launch.
• Actavis filed a motion to dismiss or declare the patent invalid on multiple grounds, including obviousness and lack of novelty.
• Discovery phase began in early 2020; the parties exchanged patent and technical disclosures.

• As of September 2023, the court has issued several rulings:

  • Denied Actavis’s motion to dismiss in March 2020.
  • Ordered Bausch to produce additional technical documentation in June 2020.
  • Scheduled a Markman hearing to resolve claim construction issues for November 2020.
  • Trial date set for September 2021, with possible extensions.

What are the primary legal issues?

• Patent validity, focusing on obviousness and anticipation.
• Infringement, based on product comparison and claim construction.
• The scope of the patent claims, particularly the interpretation of terms such as "matrix," "release mechanism," and "stability."

What technical or expert evidence has been introduced?

• Bausch’s experts have testified that the patent’s formulation offers unexpected stability benefits.
• Actavis’s experts argue that similar formulations existed prior to the patent date or are obvious extensions of prior art.
• The technical dispute hinges on the novelty of the matrix composition and the specific methods claimed.

What are potential outcomes?

• Infringement finding: If the court finds Actavis’s product infringes and the patent is valid, Bausch could obtain an injunction and damages.
• Invalidity ruling: If the court finds the patent invalid, Actavis can market its generic.
• Settlement: Parties may settle before trial, possibly involving licensing terms or market entry agreements.
• Appeal: Denial of validity or infringement could be appealed, prolonging resolution.

How does this case compare to similar patent litigations?

• Similar litigation involves pharmaceutical patent disputes, such as those between AbbVie and generic challengers.
• The case hinges on statistical and technical arguments similar to those seen in the Amgen v. Sandoz case related to biosimilars.
• Patent validity defenses frequently hinge on prior art, with courts scrutinizing the scope of claims based on expert testimony.

---

Key Takeaways

• The case underscores the importance of detailed claim construction and technical documentation.
• Court rulings on validity will significantly influence market exclusivity for Bausch’s ophthalmic formulations.
• The outcome remains uncertain until the court issues a final ruling on infringement and validity.
• Timing of trial and appeals could influence market entry by generic manufacturers.

---

FAQs

1. What patents are involved?
   U.S. Patent No. 10,321,616, covering specific ophthalmic formulations and methods.

2. What is the main legal challenge?
   The validity of the patent, with challenges to obviousness and anticipation.

3. How long could this case last?
   Trial was scheduled for September 2021; complex patent cases can extend several years, depending on appeals.

4. What are the implications for generic drug entry?
   If the patent is upheld, generic entry may be delayed until patent expiration; invalidation could lead to immediate market entry.

5. Has there been any settlement?
   No public record of settlement; proceedings suggest ongoing litigation.

---

Sources

[1] Docket entries and court filings, District of New Jersey. [2] Patent number 10,321,616. [3] Industry reports on ophthalmic drug patent litigation.

---